# Institutional Clinical and Translational Sciences Award

> **NIH NIH UL1** · UNIVERSITY OF PENNSYLVANIA · 2022 · $61,306

## Abstract

ABSTRACT OF THE FUNDED PARENT AWARD
The Institute for Translational Medicine and Therapeutics is the academic home for the CTSA in Penn. For the
past decade the specific aims of ITMAT have been and remain (i) to increase the number of investigators capable
of pursuing their research between proof of concept in cells and model systems and (ii) elucidation of the
mechanisms of human physiology, disease or drug action through intense phenotyping in small numbers of
people. The two priorities of our CTSA are to foster the field of translational therapeutics and to bridge the
pediatric to adult divide across the entire spectrum of clinical and translational science. This section describes
how these priorities have influenced the growth of this CTSA Hub and outlines our plans for the coming funding
period.

## Key facts

- **NIH application ID:** 10487653
- **Project number:** 3UL1TR001878-06S2
- **Recipient organization:** UNIVERSITY OF PENNSYLVANIA
- **Principal Investigator:** GARRET A FITZGERALD
- **Activity code:** UL1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $61,306
- **Award type:** 3
- **Project period:** 2022-02-01 → 2026-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10487653

## Citation

> US National Institutes of Health, RePORTER application 10487653, Institutional Clinical and Translational Sciences Award (3UL1TR001878-06S2). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10487653. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*